Operating Lease, Right-of-Use Asset of MoonLake Immunotherapeutics from 31 Dec 2021 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
MoonLake Immunotherapeutics quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2021 to 30 Sep 2025.
  • MoonLake Immunotherapeutics Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $1,911,000, a 41% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

MoonLake Immunotherapeutics Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $1,911,000 -$1,340,197 -41% 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $2,251,000 -$1,133,953 -34% 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $2,589,000 -$1,109,514 -30% 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $2,922,000 -$706,480 -19% 31 Dec 2024 10-Q 05 Nov 2025 2025 Q3
Q3 2024 $3,251,197 +$3,081,775 +1819% 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $3,384,953 +$3,173,715 +1502% 30 Jun 2024 10-Q 07 Aug 2024 2024 Q2
Q1 2024 $3,698,514 +$3,452,258 +1402% 31 Mar 2024 10-Q 07 May 2024 2024 Q1
Q4 2023 $3,628,480 +$3,345,900 +1184% 31 Dec 2023 10-K 26 Feb 2025 2024 FY
Q3 2023 $169,422 30 Sep 2023 10-Q 14 Nov 2023 2023 Q3
Q2 2023 $211,238 30 Jun 2023 10-Q 10 Aug 2023 2023 Q2
Q1 2023 $246,256 31 Mar 2023 10-Q 11 May 2023 2023 Q1
Q4 2022 $282,580 +$282,580 31 Dec 2022 10-K 29 Feb 2024 2023 FY
Q4 2021 $0 31 Dec 2021 10-K 20 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.